Patient adherence to olmesartan/amlodipine combinations: Fixed versus extemporaneous combinations

Journal of Managed Care and Specialty Pharmacy

Volumn 22, Issue 3, 2016, Pages 255-262

  Levi, Miriam ^a   Pasqua, Alessandro ^b   Cricelli, Iacopo ^b   Cricelli, Claudio ^b   Piccinni, Carlo ^c   Parretti, Damiano ^b   Lapi, Francesco ^b  

^a UNIVERSITY OF FLORENCE   (Italy)

^b Italian Society of General Practitioner and Primary Care (SIMG)   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; AMLODIPINE PLUS OLMESARTAN; OLMESARTAN; ANTIHYPERTENSIVE AGENT; IMIDAZOLE DERIVATIVE; TETRAZOLE DERIVATIVE;

AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; COMPARATIVE STUDY; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; ITALY; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; PATIENT COMPLIANCE; POPULATION RESEARCH; PRIMARY MEDICAL CARE; BLOOD PRESSURE; COMBINATION DRUG THERAPY; DRUG EFFECTS;

AGED; AMLODIPINE; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERTENSION; IMIDAZOLES; MALE; MEDICATION ADHERENCE; TETRAZOLES;

EID: 84981163066     PISSN: 23760540     EISSN: 23761032     Source Type: Journal    
DOI: 10.18553/jmcp.2016.22.3.255     Document Type: Article

References (52)

1. Lim SS, Vos T, Flaxman AD, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2224-60.
2. Childress B. Innovations: IHME's recently published work. IHME Impact Issue 7. April 2013. Available at http://www.healthdata.org/newsletters/impact-7/innovations. Accessed December 18, 2015.
3. Hajjar I, Kotchen JM, Kotchen TA. Hypertension: trends in prevalence, incidence, and control. Annu Rev Public Health. 2006;27:465-90.
4. Chobanian AV. Shattuck Lecture. The hypertension paradox-more uncontrolled disease despite improved therapy. N Engl J Med. 2009;361(9):878-87.
5. Nwankwo T, Yoon SS, Burt V, Gu Q. Hypertension among adults in the United States: National Health and Nutrition Examination Survey, 2011-2012 NCHS Data Brief. 2013;(133):1-8.
6. Llisterri Caro JL, Rodríguez Roca GC, Alonso Moreno FJ, et al; en representación del Grupo de Trabajo de Hipertensión Arterial de la Sociedad Española de Atención Primaria (Grupo HTA/SEMERGEN) y de los investigadores del Estudio PRESCAP 2010. Blood pressure control in hypertensive Spanish population attended in primary care setting. The PRESCAP 2010 study [article in Spanish]. Med Clin (Barc). 2012;139(15):653-61.
7. Blacher J, Halimi J-M, Hanon O, et al; Société française d'hypertension artérielle. Management of arterial hypertension in adults: 2013 guidelines of the French Society of Arterial Hypertension [article in French]. Ann Cardiol Angeiol (Paris). 2013;62(3):132-38.
8. Filippi A, Paolini I, Innocenti F, Mazzaglia G, Battaggia A, Brignoli O. Blood pressure control and drug therapy in patients with diagnosed hypertension: a survey in Italian general practice. J Hum Hypertens. 2009;23(11):758-63.
9. Grassi G, Cifkova R, Laurent S, et al. Blood pressure control and cardiovascular risk profile in hypertensive patients from central and eastern European countries: results of the BP-CARE study. Eur Heart J. 2011;32(2):218-25.
10. Corrao G, Zambon A, Parodi A, et al. Discontinuation of and changes in drug therapy for hypertension among newly-treated patients: a populationbased study in Italy. J Hypertens. 2008;26(4):819-24.
11. Burke TA, Sturkenboom MC, Lu S, Wentworth CE, Lin Y, Rhoads GG. Discontinuation of antihypertensive drugs among newly diagnosed hypertensive patients in UK general practice. J Hypertens. 2006;24(6):1193-200.
12. Mazzaglia G, Mantovani LG, Sturkenboom MCJM, et al. Patterns of persistence with antihypertensive medications in newly diagnosed hypertensive patients in Italy: a retrospective cohort study in primary care. J Hypertens. 2005;23(11):2093-100.
13. Mancia G, Laurent S, Agabiti-Rosei E, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. Blood Press. 2009;18(6):308-47.
14. Sokol MC, McGuigan KA, Verbrugge RR, Epstein RS. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care. 2005;43(6):521-30.
15. Mazzaglia G, Ambrosioni E, Alacqua M, et al. Adherence to antihypertensive medications and cardiovascular morbidity among newly diagnosed hypertensive patients. Circulation. 2009;120(16):1598-605.
16. Chowdhury R, Khan H, Heydon E, et al. Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences. Eur Heart J. 2013;34(38):2940-48.
17. World Health Organization. Adherence to Long-Term Therapies: Evidence for Action. Geneva, Switzerland: World Health Organization; 2003. Available at: http://whqlibdoc.who.int/publications/2003/9241545992.pdf. Accessed December 1, 2015.
18. Bone LR, Hill MN, Stallings R, et al. Community health survey in an urban African-American neighborhood: distribution and correlates of elevated blood pressure. Ethn Dis. 2000;10(1):87-95.
19. Saounatsou M, Patsi O, Fasoi G, et al. The influence of the hypertensive patient's education in compliance with their medication. Public Health Nurs. 2001;18(6):436-42.
20. Zullig LL, Stechuchak KM, Goldstein KM, et al. Patient-reported medication adherence barriers among patients with cardiovascular risk factors. J Manag Care Spec Pharm. 2015;21(6):479-85. Available at: http://www.amcp.org/WorkArea/DownloadAsset.aspx?id=19646.
21. Düsing R. Adverse events, compliance, and changes in therapy. Curr Hypertens Rep. 2001;3(6):488-92.
22. Benner JS, Chapman RH, Petrilla AA, Tang SS, Rosenberg N, Schwartz JS. Association between prescription burden and medication adherence in patients initiating antihypertensive and lipid-lowering therapy. Am J Health Syst Pharm. 2009;66(16):1471-77.
23. Alghurair SA, Hughes CA, Simpson SH, Guirguis LM. A systematic review of patient self-reported barriers of adherence to antihypertensive medications using the World Health Organization multidimensional adherence model. J Clin Hypertens. 2012;14(12):877-86.
24. Erkens JA, Panneman MMJ, Klungel OH, van den Boom G, Prescott MF, Herings RM. Differences in antihypertensive drug persistence associated with drug class and gender: a PHARMO study. Pharmacoepidemiol Drug Saf. 2005;14(11):795-803.
25. Veronesi M, Cicero AF, Prandin MG, et al. A prospective evaluation of persistence on antihypertensive treatment with different antihypertensive drugs in clinical practice. Vasc Health Risk Manag. 2007;3(6):999-1005. Available at: https://www.dovepress.com/articles.php?article_id=1565. Accessed December 1, 2015.
26. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001;23(8):1296-310.
27. Chrysant SG. Triple-drug, fixed-dose combinations for the treatment of hypertension: focus on olmesartan/amlodipine/hydrochlorothiazide combination. Drugs Today (Barc). 2011;47(3):197-206.
28. Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2007;28(12):1462-536.
29. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31(7):1281-357.
30. Pimenta E, Oparil S. Fixed combinations in the management of hypertension: patient perspectives and rationale for development and utility of the olmesartan-amlodipine combination. Vasc Health Risk Manag. 2008;4(3):653-64. Available at: https://www.dovepress.com/articles.php?article_id=1910. Accessed December 1, 2015.
31. Kreutz R. Olmesartan/amlodipine: a review of its use in the management of hypertension. Vasc Health Risk Manag. 2011;7:183-92.
32. Chrysant SG. Using fixed-dose combination therapies to achieve blood pressure goals. Clin Drug Investig. 2008;28(11):713-34.
33. Corrao G, Parodi A, Zambon A, et al. Reduced discontinuation of antihypertensive treatment by two-drug combination as first step. Evidence from daily life practice. J Hypertens. 2010;28(7):1584-90.
34. Degli Esposti L, Saragoni S, Buda S, Degli Esposti E. Drug adherence to olmesartan/amlodipine fixed combination in an Italian clinical practice setting. Clinicoecon Outcomes Res. 2014;6:209-16. Available at: https://www.dovepress.com/drug-adherence-to-olmesartanamlodipine-fixed-combination-in-an-italian-peer-reviewed-article-CEOR. Accessed December 1, 2015.
35. Perseguer-Torregrosa Z, Orozco-Beltrán D, Gil-Guillen V, et al. Magnitude of pharmacological nonadherence in hypertensive patients taking antihypertensive medication from a community pharmacy in Spain. J Manag Care Spec Pharm. 2014;20(12):1217-25. Available at: http://www.amcp.org/WorkArea/DownloadAsset.aspx?id=18842.
36. Italian Ministry of Health. Ministerial Decree 22 July 1996, N. 32731. Prestazioni Di Assistenza Specialistica Ambulatoriale Erogabili Nell'ambito Del Servizio Sanitario Nazionale E Relative Tariffe. Rome, Italy: Italian Ministry of Health; 1996.
37. Lawrenson R, Williams T, Farmer R. Clinical information for research; the use of general practice databases. J Public Health Med. 1999;21(3):299-304 Available at: http://jpubhealth.oxfordjournals.org/content/21/3/299.long. Accessed December 1, 2015.
38. Cricelli C, Mazzaglia G, Samani F, et al. Prevalence estimates for chronic diseases in Italy: exploring the differences between self-report and primary care databases. J Public Health Med. 2003;25(3):254-57. Available at: http://jpubhealth.oxfordjournals.org/content/25/3/254.long. Accessed December 1, 2015.
39. Mazzaglia G, Sessa E, Samani F, Cricelli C, Fabiani L. Use of computerized general practice database for epidemiological studies in Italy: a comparative study with the official national statistics. J Epidemiol Commun Health. 2004;58(Suppl 1):A133.
40. Gruppo di lavoro dell'Osservatorio Nazionale sull'Impiego dei Medicinali. L'uso Dei Farmaci in Italia. Rapporto Nazionale Anno 2012. Rome: Agenzia Italiana del Farmaco; 2013. Available at: http://www.agenziafarmaco.gov.it/sites/default/files/Rapporto_OsMed_2012.pdf. Accessed December 18, 2015.
41. Andrade SE, Kahler KH, Frech F, Chan KA. Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf. 2006;15(8):565-74; discussion 575-77.
42. Rasmussen JN, Chong A, Alter DA. Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. JAMA. 2007;297(2):177-86.
43. Cameron A, Miller D. A practitioner's guide to cluster-robust inference. J Hum Resour. 2015;50(2):317-72.
44. Bramlage P, Ketelhut R, Fronk E-M, et al. Clinical impact of patient adherence to a fixed-dose combination of olmesartan, amlodipine and hydrochlorothiazide. Clin Drug Investig. 2014;34(6):403-11.
45. Gavrielov-Yusim N, Friger M. Use of administrative medical databases in population-based research. J Epidemiol Community Health. 2014;68(3):283-87.
46. Koschack J, Marx G, Schnakenberg J, Kochen MM, Himmel W. Comparison of two self-rating instruments for medication adherence assessment in hypertension revealed insufficient psychometric properties. J Clin Epidemiol. 2010;63:299-306.
47. Thom S, Poulter N, Field J, et al.; UMPIRE Collaborative Group. Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial. JAMA. 2013;310(9):918-29.
48. Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension. 2010;55(2):399-407.
49. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(5):487-97.
50. Alacqua M, Trifirò G, Cavagna L, et al. Prescribing pattern of drugs in the treatment of osteoarthritis in Italian general practice: the effect of rofecoxib withdrawal. Arthritis Rheum. 2008;59(4):568-74.
51. Oteri A, Trifirò G, Gagliostro MS, et al. Prescribing pattern of anti-epileptic drugs in an Italian setting of elderly outpatients: a population-based study during 2004-07. Br J Clin Pharmacol. 2010;70(4):514-22.
52. Ferrajolo C, Arcoraci V, Sullo MG, et al. Pattern of statin use in southern Italian primary care: can prescription databases be used for monitoring long-term adherence to the treatment? PLoS ONE. 2014;9(7):e102146.